Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Pirfenidone for diabetic nephropathy.

Sharma K, Ix JH, Mathew AV, Cho M, Pflueger A, Dunn SR, Francos B, Sharma S, Falkner B, McGowan TA, Donohue M, Ramachandrarao S, Xu R, Fervenza FC, Kopp JB.

J Am Soc Nephrol. 2011 Jun;22(6):1144-51. doi: 10.1681/ASN.2010101049. Epub 2011 Apr 21.

2.

Pirfenidone is renoprotective in diabetic kidney disease.

RamachandraRao SP, Zhu Y, Ravasi T, McGowan TA, Toh I, Dunn SR, Okada S, Shaw MA, Sharma K.

J Am Soc Nephrol. 2009 Aug;20(8):1765-75. doi: 10.1681/ASN.2008090931. Epub 2009 Jul 2.

3.

Stimulation of urinary TGF-beta and isoprostanes in response to hyperglycemia in humans.

McGowan TA, Dunn SR, Falkner B, Sharma K.

Clin J Am Soc Nephrol. 2006 Mar;1(2):263-8. Epub 2005 Dec 28.

4.

Transforming growth factor-beta: a clinical target for the treatment of diabetic nephropathy.

McGowan TA, Zhu Y, Sharma K.

Curr Diab Rep. 2004 Dec;4(6):447-54. Review.

PMID:
15539010
5.

TGF-beta-induced Ca(2+) influx involves the type III IP(3) receptor and regulates actin cytoskeleton.

McGowan TA, Madesh M, Zhu Y, Wang L, Russo M, Deelman L, Henning R, Joseph S, Hajnoczky G, Sharma K.

Am J Physiol Renal Physiol. 2002 May;282(5):F910-20.

6.

Effect of anti-transforming growth factor-beta antibodies in cyclosporine-induced renal dysfunction.

Islam M, Burke JF Jr, McGowan TA, Zhu Y, Dunn SR, McCue P, Kanalas J, Sharma K.

Kidney Int. 2001 Feb;59(2):498-506.

7.
8.

Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice.

Ziyadeh FN, Hoffman BB, Han DC, Iglesias-De La Cruz MC, Hong SW, Isono M, Chen S, McGowan TA, Sharma K.

Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):8015-20.

9.

TGF-beta in diabetic kidney disease: role of novel signaling pathways.

Sharma K, McGowan TA.

Cytokine Growth Factor Rev. 2000 Mar-Jun;11(1-2):115-23. Review.

PMID:
10708959
10.

Captopril-induced reduction of serum levels of transforming growth factor-beta1 correlates with long-term renoprotection in insulin-dependent diabetic patients.

Sharma K, Eltayeb BO, McGowan TA, Dunn SR, Alzahabi B, Rohde R, Ziyadeh FN, Lewis EJ.

Am J Kidney Dis. 1999 Nov;34(5):818-23. Erratum in: Am J Kidney Dis 2000 Mar;35(3):572.

PMID:
10561136
11.

Increased renal production of transforming growth factor-beta1 in patients with type II diabetes.

Sharma K, Ziyadeh FN, Alzahabi B, McGowan TA, Kapoor S, Kurnik BR, Kurnik PB, Weisberg LS.

Diabetes. 1997 May;46(5):854-9.

PMID:
9133555

Supplemental Content

Loading ...
Support Center